

Q-LINEA HAS RECEIVED FIRST ORDER ON ASTAR

Q-linea AB (publ) (OMX:QLINEA), today announced that the company's global sales partner Thermo Fisher Scientific has placed their first order on ASTar® instruments and consumables. The value of the order exceeds SEK 8 million.

ASTar is a fully automatic system for antibiotic susceptibility testing (AST) with little hands-on time, ease-of-use and capabilities to deliver a broad answer within approximately six hours for positive blood cultures.

This order aims to enable commercial readiness for the first customer orders after launch. Commercial launch can take place as soon as the clinical study is finalized and ASTar is CE-IVD approved. ASTar's first application is focused on improving the diagnostics for patients with blood stream infections, where sepsis is the most common condition.

The value of the first order from Thermo Fisher Scientific exceeds SEK 8 million. The structure of the order also includes a pre-payment for a binding order for the next six months.

Both Thermo Fisher Scientific and Q-linea believe in a strong growth for ASTar and aim for a long term successful and strong ramp-up after the first controlled launch phase.

"We are of course very excited to see the first order coming in before the completion of the clinical study. This enables us together to be ready for launch and shows the trust our partner has in a successful outcome of the clinical study. I also think that the structure with binding orders and pre-payment is important as we move into the commercial phase for Q-linea," said Jonas Jarvius, CEO of Q-linea.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB

Jonas.Jarvius@qlinea.com

+46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB

Anders.Lundin@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-03-10 12:56 CET.

Attachments

Q-linea has received first order on ASTar